Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States
鉴定两种对非复制结核分枝杆菌具有活性的新型化合物的分子靶标,并描述假定靶标 InhA 在非复制状态下的作用
基本信息
- 批准号:10083173
- 负责人:
- 金额:$ 17.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-25 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AgarAnaerobic BacteriaBiological AssayBiologyBoronCell CommunicationCell WallClinicalCollaborationsCommunicable DiseasesDNA Sequence AlterationDataDevelopmentDevelopment PlansDoseDrug TargetingEnvironmentEnzymesExposure toFaceFoundationsFutureGene MutationGenetic TranscriptionGenus MycobacteriumGoalsGrowthHeterogeneityHumanHuman bodyImmuneIn VitroIncubatedIsoniazid resistanceKineticsKnock-outLearningLinkLipidsLiteratureMedicineMethodsModelingModificationMolecular TargetMutationMycobacterium smegmatisMycobacterium tuberculosisMycolic AcidNADHNew YorkNutrientOutcomePhagosomesPharmaceutical PreparationsPhenotypePhysiciansPhysiologyPredispositionProcessPropertyPublishingResearchResearch PersonnelResistanceResourcesRoleScientistSecondary toSerumStarvationStressStress TestsTechniquesTestingTherapeuticTrainingTranslational ResearchTuberculosisWorkantibiotic toleranceantimicrobialbasebiological adaptation to stresscareercareer developmentchemical propertydesignexperiencegenetic manipulationimprovedin vivoinhibitor/antagonistisoniazidknock-downlipidomelipidomicsmacrophagemetabolomemetabolomicsmutantneutrophilnovelpathogenphysiologic stressorresilienceresponseskillstherapeutic developmenttuberculosis drugstuberculosis treatment
项目摘要
Project Summary
Candidate and career development plan: Dr. Kohta Saito is an Infectious Diseases physician committed to
translational research in the fields of antimicrobial discovery and biology of non-replicating pathogens,
specifically Mycobacterium tuberculosis (Mtb). His overarching goal is to become an independent physician-
scientist pursuing questions of pathogen stress-response and antibiotic tolerance in order to discover novel
treatment methods. In the short term, his goals are: 1. To gain skills in the genetic manipulation of Mtb, 2. To
learn lipidomic techniques and apply them to the physiology of pathogen response to drugs and host stress, 3.
To hone expertise in the study of immune cell interaction with Mtb, 4. To transition to an independent investigator.
Environment: Weill Cornell Medicine (New York, NY) is well suited to develop Dr. Saito's career and already
equipped to accomplish the proposed research. A large infectious diseases division, tri-institutional resources,
and a collaborative TB Research Unit provide fertile ground for the appropriate training Dr. Saito will undertake.
Research: The proposed work extends Dr. Saito's experience with Mtb that become tolerant to antibiotics upon
exposure to stresses that cause entry into a non-replicative (NR) state. He will use two compounds that kill NR
mycobacteria and identify the NR target. Specifically, he will test whether InhA, a cell wall synthesizing enzyme,
is the relevant target. He will also test the essentiality of InhA in NR conditions without compound exposure.
Specific Aim 1. Identify the NR target of two novel compounds that kill NR mycobacteria. We hypothesize that
two compounds, AN1 and AN2, kill NR Mtb via direct inhibition of InhA. We will test this with 3 methods: 1.
Recombineering InhA mutations in Mtb and testing susceptibility to AN1 and AN2 in NR condtions, 2. creating
conditional knockdowns of InhA in Mtb and assessing their susceptibility to AN1 and AN2, and 3. comparing lipid
profiles of NR Mtb before and after compound exposure.
Specific Aim 2. Determine the essentiality of InhA in varied models of NR Mtb. We hypothesize that InhA is
essential to Mtb in NR states. We will create a conditional InhA knockout strain, and then assess its viability in
relevant stress conditions, including exposure to human macrophages, neutrophils, and serum. Metabolomic
and lipidomic changes that occur with knockdown strains in NR conditions will also be investigated.
Significance: The proposed work will define a process vital to survival of Mtb in NR states, and delineate the
role of InhA in NR states. This will advance the field's understanding of Mtb response to physiologic stresses,
and provide drug targets that promise to shorten tuberculosis therapy.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kohta Saito其他文献
Kohta Saito的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kohta Saito', 18)}}的其他基金
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States
鉴定两种对非复制结核分枝杆菌具有活性的新型化合物的分子靶标,并描述假定靶标 InhA 在非复制状态下的作用
- 批准号:
10320910 - 财政年份:2019
- 资助金额:
$ 17.2万 - 项目类别:
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States
鉴定两种对非复制结核分枝杆菌具有活性的新型化合物的分子靶标,并描述假定靶标 InhA 在非复制状态下的作用
- 批准号:
10538631 - 财政年份:2019
- 资助金额:
$ 17.2万 - 项目类别:
相似海外基金
Identification and isolation of anaerobic bacteria that degrade bacterial cell wall
降解细菌细胞壁的厌氧菌的鉴定与分离
- 批准号:
22H02487 - 财政年份:2022
- 资助金额:
$ 17.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Enzymology of cofactor and amino acid metabolism in anaerobic bacteria
厌氧菌辅助因子和氨基酸代谢的酶学
- 批准号:
RGPIN-2022-03200 - 财政年份:2022
- 资助金额:
$ 17.2万 - 项目类别:
Discovery Grants Program - Individual
High-throughput isolation of anaerobic bacteria
厌氧菌的高通量分离
- 批准号:
572711-2022 - 财政年份:2022
- 资助金额:
$ 17.2万 - 项目类别:
University Undergraduate Student Research Awards
Elucidating the mechanisms of O2-sensitivity of anaerobic bacteria Bifidobacterium.
阐明厌氧菌双歧杆菌的 O2 敏感性机制。
- 批准号:
22K07058 - 财政年份:2022
- 资助金额:
$ 17.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automatic and accurate identification of aerobic bacteria, anaerobic bacteria, yeasts, and fungi in clinical samples derived from animals and from feed for pets
自动、准确地鉴定来自动物和宠物饲料的临床样品中的需氧细菌、厌氧细菌、酵母菌和真菌
- 批准号:
10440741 - 财政年份:2021
- 资助金额:
$ 17.2万 - 项目类别:
Regulation of virulence in fungi under coculture condition with anaerobic bacteria
厌氧菌共培养条件下真菌毒力的调节
- 批准号:
21K07009 - 财政年份:2021
- 资助金额:
$ 17.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Polymicrobial interactions between commensal obligate anaerobic bacteria and cystic fibrosis pathogen P. aeruginosa
共生专性厌氧菌与囊性纤维化病原体铜绿假单胞菌之间的多种微生物相互作用
- 批准号:
10275319 - 财政年份:2021
- 资助金额:
$ 17.2万 - 项目类别:
Platform for the automated isolation and characterization of anaerobic bacteria
厌氧菌自动分离和表征平台
- 批准号:
445552570 - 财政年份:2020
- 资助金额:
$ 17.2万 - 项目类别:
Major Research Instrumentation
Development of therapy for triple negative breast cancer using anaerobic bacteria
利用厌氧菌开发三阴性乳腺癌疗法
- 批准号:
19K16452 - 财政年份:2019
- 资助金额:
$ 17.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of gene engineering method for anaerobic bacteria for efficient bio-hydrogen production
开发厌氧菌高效生物制氢的基因工程方法
- 批准号:
18K11708 - 财政年份:2018
- 资助金额:
$ 17.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)